Designer drugs: mechanism of action and adverse effects
Open accessThe DOI matches its Crossref record; 658 of the 659 references it cites were found in a registry or an index.
Abstract
Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Agonism at μ-opioid receptors and γ-aminobutyric acid-A (GABA A ) or GABA B receptors mediates the pharmacological effects of sedatives, which may induce cardiorespiratory depression. Dissociative designer drugs primarily act as N -methyl- d -aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 (CB 1 ) receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A (5-HT 2A ) receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The precipitous increase in novel and designer drugs (eg, cathinones, amphetamines) in the market complicates the clinical picture.3”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–658 of 658
Nia, A. B., Mann, C. L., Spriggs, S. A., DeFrancisco, D., Carbonaro, S., Parvez, L., GALYNKER, I. I., Perkel, C., & Hurd, Y. L. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12539 · Cited by 19
Quantitative structure–activity relationship studies of threo-methylphenidate analogs
Misra, M., Shi, Q., Ye, X., Gruszecka‐Kowalik, E., Bu, W., Liu, Z., Schweri, M. M., Deutsch, H. M., & Venanzi, C. A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.034 · Cited by 18
Delayed Rhabdomyolysis After Ecstasy Use
Halachanova, V., Sansone, R. A., & McDonald, S. (2001) · Mayo Clinic Proceedings · doi:10.4065/76.1.112 · Cited by 18
Gaunitz, F., Lehmann, S., Thomas, A., Thevis, M., Rothschild, M. A., & Mercer‐Chalmers‐Bender, K. (2018) · International Journal of Legal Medicine · doi:10.1007/s00414-018-1911-8 · Cited by 18
Kriikku, P., Pelander, A., Rasanen, I., & Ojanperä, I. A. (2019) · Forensic Science International · doi:10.1016/j.forsciint.2019.04.030 · Cited by 18
An autopsy case of multiple psychotropic drug poisoning.
Tanaka, N., Kinoshita, H., Nishiguchi, M., Jamal, M., Kumihashi, M., Takahashi, M., Nishio, H., & Ameno, K. (2011) · PubMed · Cited by 17
Methoxetamine: prevalence of use in the USA and UK and associated urinary problems
Lawn, W., Borschmann, R., Cottrell, A. M., & WINSTOCK, A. R. (2014) · Journal of Substance Use · doi:10.3109/14659891.2014.966345 · Cited by 17
Shah, M. K., Garg, J., Patel, B. D., Guthier, J. L., & Freudenberger, R. S. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.055 · Cited by 17
Noble, C., Holm, N. B., Mardal, M., & Línnet, K. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.07.018 · Cited by 17
Glanville, J., Dargan, P. I., & Wood, D. M. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2472 · Cited by 16
Multiple Fatalities Involving a New Designer Drug: Para-Methyl-4-Methylaminorex
Cosbey, S. H., Kirk, S., McNaul, M., Peters, L., Prentice, B., Quinn, A., Elliott, S. P., Brandt, S. D., & Archer, R. (2014) · Journal of Analytical Toxicology · doi:10.1093/jat/bku031 · Cited by 16
White, J. C., Wood, D. M., Hill, S. L., Eddleston, M., Officer, J., Dargan, P. I., Dunn, M., & Thomas, S. H. L. (2019) · Clinical Toxicology · doi:10.1080/15563650.2018.1538519 · Cited by 16
Markowitz, J. S., Zhu, H., & Patrick, K. S. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0074 · Cited by 15
Phenazepam is currently being misused in the UK
Maskell, P., Paoli, G. D., Seetohul, L. N., & Pounder, D. J. (2011) · BMJ · doi:10.1136/bmj.d4207 · Cited by 15
Fuse‐Nagase, Y., & Nishikawa, T. (2013) · Addiction Science & Clinical Practice · doi:10.1186/1940-0640-8-9 · Cited by 15
Vogel, M., Bucher, P., Strasser, J., Liechti, M. E., Krähenbühl, S., & Dürsteler, K. M. (2016) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1130883 · Cited by 15
Self-citationMayer, F. P., Schmid, D., Holy, M., Daws, L. C., & Sitte, H. H. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.09.008 · Cited by 15
Pharmacological characterization of the aminorex analogs 4-MAR, 4,4′-DMAR, and 3,4-DMAR
Rickli, A., Kolaczynska, K. E., Hoener, M. C., & Liechti, M. E. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.02.011 · Cited by 15
Self-citationA case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids
Kamel, M., & Thajudeen, B. (2015) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.160222 · Cited by 14
Leibu, E., Garakani, A., McGonigle, D. P., Liebman, L. S., Loh, D. A., Bryson, E. O., & Kellner, C. H. (2013) · Journal of Ect · doi:10.1097/yct.0b013e318290fa36 · Cited by 14
Severe rhabdomyolysis and acute kidney injury associated with methoxphenidine
Lam, R. P. K., Yip, W. L., Tsui, M. S. H., Ng, S. W., Ching, C. K., & Mak, T. W. L. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1157724 · Cited by 14
Acute Methiopropamine Intoxication After “Synthacaine” Consumption
Daveluy, A., Castaing, N., Cherifi, H., Richeva, C., Humbert, L., Faure, I., Labadie, M., Allorge, D., Haramburu, F., Molimard, M., et al. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw073 · Cited by 14
Synthetic Cannabis Analogues and Suicidal Behavior: Case Report
Oliveira, P., Morais, A. S. F., & Madeira, N. G. G. F. (2017) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000335 · Cited by 14
Zahran, T. E., Gerona, R. R. L., Morgan, B., & Pomerleau, A. C. (2018) · Clinical Toxicology · doi:10.1080/15563650.2018.1534241 · Cited by 14
5‐(2‐aminopropyl)indole: A new player in the drama of ‘legal highs’ alerts the community
Katselou, M. G., Papoutsis, I. I., Nikolaou, P., Spiliopoulou, C., & Athanaselis, S. (2014) · Drug and Alcohol Review · doi:10.1111/dar.12136 · Cited by 13
Drug-induced acute psychosis in an adolescent first-time user of 4-HO-MET
Täljemark, J., & Johansson, B. A. (2012) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-012-0282-9 · Cited by 13
Acute myocardial infarction triggered by use of synthetic cannabis
Mills, B., Dishner, E., & Velasco, C. (2018) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2017.1416243 · Cited by 13
Acute Liver Injury Induced by Synthetic Cannabinoid Abuse
Shahbaz, A., Gaviria, R. R., Shahid, M. F., Yasin, M. A., Ashraf, A., & Zaman, M. A. (2018) · Cureus · doi:10.7759/cureus.3257 · Cited by 13
Bravo, R. R., Carmo, H., Silva, J. P., Valente, M. J., Carvalho, F. D., Bastos, M. D. L., & da Silva, D. D. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02638-9 · Cited by 13
Ecstasy (3,4-Methylenedioxymethamphetamine)-Induced Inappropriate Antidiuretic Hormone Secretion
Farah, R. E., & Farah, R. (2008) · Pediatric Emergency Care · doi:10.1097/pec.0b013e3181850c91 · Cited by 12
Popławska, M., & Błażewicz, A. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2467 · Cited by 12
Shoff, E. N., Kahl, J. H., Hime, G. W., Coburn, M., & Boland, D. M. (2019) · Journal of Analytical Toxicology · doi:10.1093/jat/bkz061 · Cited by 12
2C Series Phenethylamine Derivative Exposures in Texas
Forrester, M. B. (2012) · Substance Abuse · doi:10.1080/08897077.2012.715623 · Cited by 11
Myocardial Ischemia with Cannabinoid Use in an Adolescent
Mehta, J. J., Mahendran, A., Bajaj, R. K., & Doshi, A. R. (2017) · Cureus · doi:10.7759/cureus.1899 · Cited by 11
Faroqui, R. M., Mena, P., Wolfe, A. R., Bibawy, J. M., Visvikis, G. A., & Mantello, M. T. (2018) · Radiology Case Reports · doi:10.1016/j.radcr.2018.02.023 · Cited by 10
Seither, J. Z., Reidy, L. J., & Boland, D. M. (2019) · Journal of Analytical Toxicology · doi:10.1093/jat/bkz043 · Cited by 10
Inan, F., Brunt, T. M., Contrucci, R. R., Hondebrink, L., & Franssen, E. J. F. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000725 · Cited by 10
The involvement of dopamine in the central actions of bupropion, a new antidepressant [proceedings].
Canning, H., Goff, D., Leach, M. J., Miller, A. A., Tateson, J. E., & Wheatley, P. L. (1979) · PubMed Central · Cited by 9
Gamma Hydroxybutyrate Use: Exploring the Influence of Outcome Expectancies Through Memory Modeling
Brown, P., Alfonso, J., & Dunn, M. E. (2011) · American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00113.x · Cited by 9
Diethylpropion in the treatment of obesity.
Cunningham, G. (1963) · PubMed · Cited by 9
McLaughlin, G., Baumann, M. H., Kavanagh, P. V., Morris, N. M., Power, J. D., Dowling, G., Twamley, B., O’Brien, J. E., Hessman, G., Westphal, F., et al. (2018) · Drug Testing and Analysis · doi:10.1002/dta.2396 · Cited by 9
Severe phenibut poisoning: An adolescent case cluster
Isoardi, K., Kulawickrama, S., & Isbister, G. K. (2019) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.14605 · Cited by 9
COMPARATIVE PHYSIOLOGICAL ACTIONS OF PHENYL-, THIENYL- AND FURYLISOPROPYLAMINES
Alles, G. A., & Feigen, G. A. (1941) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)03876-5 · Cited by 8
A New Stimulant of Abuse: 5-(2-aminopropyl)indole
Coppola, M., & Mondola, R. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12091168 · Cited by 8
A Curious Case of Inhalation Fever Caused by Synthetic Cannabinoid
Chinnadurai, T., Shrestha, S., & Ayinla, R. (2016) · American Journal of Case Reports · doi:10.12659/ajcr.898500 · Cited by 8
Delirium and High Creatine Kinase and Myoglobin Levels Related to Synthetic Cannabinoid Withdrawal
Yazıcı, A. B., Yazıcı, E., & Erol, A. (2017) · Case Reports in Medicine · doi:10.1155/2017/3894749 · Cited by 8
Benesch, M. G. K., & Iqbal, S. J. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-224995 · Cited by 8
Complication of Spice Use in a Deployed Combat Setting—Seizure while on Duty
Bebarta, V. S., Ramirez, S., & Varney, S. M. (2012) · American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00264.x · Cited by 7
Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians
Sweet, G., Kim, S., Martin, S. A., Washington, N. B., & Brahm, N. C. (2017) · Mental Health Clinician · doi:10.9740/mhc.2017.07.156 · Cited by 7
Pulmonary embolism due to synthetic cannabinoid use: Case report
Yırgın, G. (2018) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2018.84425 · Cited by 7
Occurrence of Takotsubo Cardiomyopathy after Synthetic Cannabinoid Consumption.
Mohammed, D. (2019) · PubMed Central · doi:10.22122/ahj.v11i3.239 · Cited by 7
AYDIN, G., & Bakar, B. (2019) · Bulletin of Emergency and Trauma · doi:10.29252/beat-0703019 · Cited by 6
Fawzy, M., Wong-Morrow, W. S., Beaumont, A. C., & Farmer, C. (2017) · CEN Case Reports · doi:10.1007/s13730-017-0263-4 · Cited by 5
Skryabin, V. Y., & Винникова, М. А. (2018) · Journal of Addictive Diseases · doi:10.1080/10550887.2019.1627635 · Cited by 5
A case of drowning whilst under the influence of brotizolam, flunitrazepam and ethanol.
Tanaka, N., Kinoshita, H., Jamal, M., Ohkubo, E., Kumihashi, M., & Ameno, K. (2011) · PubMed · Cited by 4
Acute Eosinophilic Pneumonia with Respiratory Failure Induced by Synthetic Cannabinoid Inhalation
Öcal, N., Doğan, D., Çiçek, A. F., Yücel, O., & Tozkoparan, E. (2016) · Balkan Medical Journal · doi:10.5152/balkanmedj.2016.151145 · Cited by 4
Synthetic Cannabis and Myocardial Infarction: A Complication Less Known!
Hirapara, K., & Aggarwal, R. (2015) · Psychosomatics · doi:10.1016/j.psym.2015.07.009 · Cited by 2
Clinical Aspects Related to Methylphenidate-Based NPS
Lüthi, D., & Liechti, M. E. (2018) · Routledge eBooks · doi:10.4324/9781315158082-13 · Cited by 2
Self-citation
Research works printed but not linked: 5
- Heim R (2004) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts. Dissertation, Freie Universität Berlin. https://refubium.fu-berlin.de/bitstream/handle/fub188/11995/0_RalfHeimTitelblatt.pdf?sequence=1&isAllowed=y. Accessed 7 Jan 2020
- Sanchez S (1929) Sur un homologue de l’éphédrine. Bull Soc Chim Fr 45:284–286
- Thorlacius K, Borna C, Personne M (2008) Bromo-dragonfly–livsfarlig missbruksdrog. Kan ge vävnadsnekros, visar det första beskrivna fallet. Lakartidningen 105(16):1199–200
- Topeff J, Ellsworth H, Willhite L, Bangh S, Edwards E, Cole J (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila) 49:526
- Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn
Cited by
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder
(2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001299 · Cited by 78
Understanding the Mechanisms of Action and Effects of Drugs of Abuse
Anghel, D.-M. C., Nițescu, G. V., Tiron, A. T., Guțu, C. M., & Baconi, D. L. (2023) · Molecules · doi:10.3390/molecules28134969 · Cited by 124
A review of synthetic cathinones emerging in recent years (2019–2022)
Kuropka, P., Zawadzki, M., & Szpot, P. (2022) · Forensic Toxicology · doi:10.1007/s11419-022-00639-5 · Cited by 79
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
Mohr, A. L. A., Logan, B. K., Fogarty, M. F., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Huestis, M. A., & Ropero-Miller, J. D. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac023 · Cited by 68
Metadata
- Authors
- Luethi, D., & Liechti, M. E.
- Affiliations
- TU Wien (AT)
- University of Basel (CH)
- Corresponding author
- Luethi, Dino
- Venue
- Archives of Toxicology
- Published
- 2020-04
- Volume
- 94
- Issue
- 4
- Pages
- 1085-1133
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC7225206
- OpenAlex
- W3014121938
- Cited by
- 262
- References
- 659
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 43 · 2023: 42 · 2022: 55 · 2021: 35 · 2020: 13
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-03-03)
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 5 d)
- Locations
- Archives of Toxicology (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_181809)
- Bundesamt für Gesundheit (16.921318)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- new psychoactive substances, mechanism of action, adverse drug reactions, stimulants, cathinone, monoamine transporters, sympathomimetic effects, sedatives, mu-opioid receptor agonism, GABA receptors, cardiorespiratory depression, dissociative drugs, NMDA receptor antagonists, ketamine, synthetic cannabinoids, CB1 receptor, serotonergic psychedelics, 5-HT2A receptor, drug screening, polydrug use
- MeSH terms
- Central Nervous System Stimulants, Cannabinoids, Hallucinogens, Humans, Psychotropic Drugs, Serotonin, Illicit Drugs, Designer Drugs, Molecular Structure, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.